CG Oncology CEO Arthur Kuan buys 30,000 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
CG Oncology, Inc. (CGON) Chief Executive Officer Arthur Kuan purchased 30,000 shares at $78.88 per share on November 18, 2026. His reported direct holdings after the purchase were 228,916 shares. No Rule 10b5-1 plan is reported.
Insider Trade Summary
Net Buyer: 30,000.32 shares
Net Buy
1 txn
Insider
Kuan Arthur
Role
Chief Executive Officer
Bought
30,000.32 shs ($2.37M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 30,000.32 | $78.88 | $2.37M |
Holdings After Transaction:
Common Stock — 228,916.32 shares (Direct)
Key Figures
Shares purchased: 30,000 shares
Purchase price: $78.88 per share
Direct holdings after purchase: 228,916 shares
3 metrics
Shares purchased
30,000 shares
November 18, 2026
Purchase price
$78.88 per share
Purchase on November 18, 2026
Direct holdings after purchase
228,916 shares
Reported after the November 18, 2026 purchase
Key Terms
Rule 10b5-1
1 terms
Rule 10b5-1 financial
"No Rule 10b5-1 plan is reported"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.